262 related articles for article (PubMed ID: 31536779)
41. ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo.
Cheng Y; Kerppola RE; Kerppola TK
Endocr Relat Cancer; 2016 Apr; 23(4):1-19. PubMed ID: 26843528
[TBL] [Abstract][Full Text] [Related]
42. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma.
Landwehr LS; Altieri B; Schreiner J; Sbiera I; Weigand I; Kroiss M; Fassnacht M; Sbiera S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474412
[TBL] [Abstract][Full Text] [Related]
43. A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression.
Wang T; Subramanian C; Blagg BSJ; Cohen MS
Surgery; 2020 Jan; 167(1):233-240. PubMed ID: 31561992
[TBL] [Abstract][Full Text] [Related]
44. Feminizing Adrenocortical Carcinoma: The Source of Estrogen Production and the Role of Adrenal-Gonadal Dedifferentiation.
Wu L; Xie J; Jiang L; Su T; Ye L; Zhou W; Jiang Y; Zhang C; Ning G; Wang W
J Clin Endocrinol Metab; 2018 Oct; 103(10):3706-3713. PubMed ID: 30053001
[TBL] [Abstract][Full Text] [Related]
45. A Micellar Mitotane Formulation with High Drug-Loading and Solubility: Physico-Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models.
Haider MS; Schreiner J; Kendl S; Kroiss M; Luxenhofer R
Macromol Biosci; 2020 Jan; 20(1):e1900178. PubMed ID: 31596553
[TBL] [Abstract][Full Text] [Related]
46. LncRNA HOTAIR participates in the development and progression of adrenocortical carcinoma via regulating cell cycle.
Yan ZC; He L; Qiu JH; Deng WT; Lu JR; Yuan Z; Liu DJ; Zheng RQ; Jiang W
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6640-6649. PubMed ID: 30402836
[TBL] [Abstract][Full Text] [Related]
47. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
[TBL] [Abstract][Full Text] [Related]
48. Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics.
Zhang J; Wu L; Su T; Liu H; Jiang L; Jiang Y; Wu Z; Chen L; Li H; Zheng J; Sun Y; Peng H; Han R; Ning G; Ye L; Wang W
Front Endocrinol (Lausanne); 2024; 15():1365321. PubMed ID: 38779454
[TBL] [Abstract][Full Text] [Related]
49. IGF2 role in adrenocortical carcinoma biology.
Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
[TBL] [Abstract][Full Text] [Related]
50. Management of Adrenocortical Carcinoma.
Jasim S; Habra MA
Curr Oncol Rep; 2019 Feb; 21(3):20. PubMed ID: 30798468
[TBL] [Abstract][Full Text] [Related]
51. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
52. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
Germano A; Rapa I; Volante M; Lo Buono N; Carturan S; Berruti A; Terzolo M; Papotti M
Mol Cell Endocrinol; 2014 Jan; 382(1):1-7. PubMed ID: 24018612
[TBL] [Abstract][Full Text] [Related]
53. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
[TBL] [Abstract][Full Text] [Related]
54. FSCN1 as a new druggable target in adrenocortical carcinoma.
Ruggiero C; Tamburello M; Rossini E; Zini S; Durand N; Cantini G; Cioppi F; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Landwehr LS; Weigand I; Kurlbaum M; Zizioli D; Turtoi A; Yang S; Berruti A; Luconi M; Sigala S; Lalli E
Int J Cancer; 2023 Jul; 153(1):210-223. PubMed ID: 36971100
[TBL] [Abstract][Full Text] [Related]
55. Metastatic adrenocortical carcinoma with a prolonged response to mitotane.
Pal SK; Gartrell B; Olsson CA; Stein CA
Oncology (Williston Park); 2014 Jul; 28(7):624-5, 642. PubMed ID: 25144285
[No Abstract] [Full Text] [Related]
56. The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells.
Catalano R; Giardino E; Treppiedi D; Mangili F; Morelli V; Elli FM; Serban AL; Luconi M; Mannelli M; Spada A; Arosio M; Mantovani G; Peverelli E
Cancer Lett; 2021 Jan; 497():77-88. PubMed ID: 33075426
[TBL] [Abstract][Full Text] [Related]
57. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.
Smith DC; Kroiss M; Kebebew E; Habra MA; Chugh R; Schneider BJ; Fassnacht M; Jafarinasabian P; Ijzerman MM; Lin VH; Mohideen P; Naing A
Invest New Drugs; 2020 Oct; 38(5):1421-1429. PubMed ID: 31984451
[TBL] [Abstract][Full Text] [Related]
58. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
59. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
60. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]